CSI Market
Sign In | Register

Silence Therapeutics Plc (SLN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SLN quarterly Cash Flow →
The data below summarizes Silence Therapeutics Plc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-88.61
Depreciation & amortization0.31
Amortization of Other Assets0.24
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation8.07
Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss0.00
Financial Instruments and Foreign Currency Transaction-8.47
Adjustments For Sharebased Payments-
Adjustments For Gain Loss On Derivative Financial Instrument-
Adjustments For Finance Costs-
Adjustments For Finance Income-
Adjustments For Decrease Increase In Other Current Assets-
Adjustments For Decrease Increase In Derivative Financial Instruments-
Adjustments For Decrease Increase In Current Financial Assets At Amortised Cost Other-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Decrease Increase In Contract Liabilities-
Net Foreign Exchange Impacts11.02
Other Income-3.48
Increase Decrease In Research And Development Benefit Receivable4.04
Increase Decrease In Trade And Other Payables-4.08
Increase Decrease In Contract With Customer Liability-0.33
Increase Decrease In Operating Lease Liability-0.17
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities0.00
Increase (Decrease) in Accounts Receivable-1.02
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-6.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-62.27
Investing Activities
Capital Expenditures0.06
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-47.94
Discontinued operations0.00
Net Cash Flow from Investing Activities-47.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-121.33
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations121.33
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.02
Effect of exchange rate on cash flow0.20
Discontinued operations0.00
Free Cash Flow-62.22
Total Cash Flow-110.25
4 historic quarters locked

Sign in to unlock the full Silence Therapeutics Plc cash flow history.

Sign In Create Free Account

About Silence Therapeutics Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 5, 2026
  • Source: sln-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-092591

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License